We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long‐term use of low‐dose aspirin for cancer prevention: A 10‐year population cohort study in Hong Kong.
- Authors
Tsoi, Kelvin K.F.; Ho, Jason M.W.; Chan, Felix C.H.; Sung, Joseph J.Y.
- Abstract
Aspirin, commonly used for prevention of cardiovascular and cerebrovascular diseases, has been found to possess protective effects against cancer development in the Western populations. Such effects among Asian populations remain uncertain. The objective of this study is to investigate the use of aspirin on prevention of different cancers among Chinese users. This population‐based study utilized database from the Hong Kong Hospital Authority; adults with aspirin prescription for at least 6 months between 2000 and 2004 were included and followed up until 2013. Aspirin users were age‐sex matched with non‐aspirin users at a 1:2 ratio. Incidences of cancer were the primary outcome measured by relative risk (RR). A total of 204,170 aspirin users and 408,339 non‐aspirin users were included, with the mean age 67.5 years, 7.7 years average duration of aspirin prescription and 80 mg as the median dose of aspirin. Cancer incidences were found in 26,929 (13.2%) aspirin users and 70,755 (17.3%) non‐aspirin users. Compared with patients who had not been prescribed aspirin, aspirin usage led to significant reduction of cancers in liver (RR: 0.49), stomach (RR: 0.42), colorectum (RR: 0.71), lung (RR: 0.65), pancreas (RR: 0.54), oesophagus (RR: 0.59) and leukaemia (RR: 0.67). There was no demonstrable reduction of kidney cancer, bladder cancer, prostate cancer and multiple myeloma in association with the usage of aspirin. Risk of breast cancer was shown to marginally increase (RR: 1.14) with aspirin usage. This study demonstrated that the long‐term use of low‐dose aspirin is associated with the reduction in risk of various cancers but not for breast cancer. Further investigation is needed before promoting aspirin as a primary chemoprotective agent. What's new? While long‐term use of low‐dose aspirin is associated with reductions in the risk of certain cancers, including colorectal cancer, most investigations of aspirin use and cancer prevention have focused on Western populations. Here, the authors examined cancer incidence and aspirin usage in a Chinese cohort. Long‐term aspirin use was linked to reduced risk of multiple cancer types, including leukemia and cancers of the liver, stomach, colorectum, pancreas, lung, and esophagus. Reductions were not observed for multiple myeloma or cancers of the kidney, prostate, or bladder, and risk of breast cancer was increased among patients with prolonged aspirin use.
- Publication
International Journal of Cancer, 2019, Vol 145, Issue 1, p267
- ISSN
0020-7136
- Publication type
Article
- DOI
10.1002/ijc.32083